Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Short Interest Update

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 3,150,000 shares, a decline of 26.4% from the August 15th total of 4,280,000 shares. Based on an average daily trading volume, of 2,710,000 shares, the days-to-cover ratio is currently 1.2 days.

Allena Pharmaceuticals stock opened at $0.91 on Tuesday. Allena Pharmaceuticals has a fifty-two week low of $0.75 and a fifty-two week high of $2.78. The firm has a market capitalization of $72.53 million, a PE ratio of -0.99 and a beta of 2.17. The company’s 50-day moving average is $0.95 and its 200-day moving average is $1.17. The company has a debt-to-equity ratio of 0.81, a current ratio of 3.63 and a quick ratio of 3.63.

Allena Pharmaceuticals (NASDAQ:ALNA) last announced its quarterly earnings results on Monday, August 9th. The company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.03). As a group, analysts expect that Allena Pharmaceuticals will post -0.81 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in ALNA. Vanguard Group Inc. grew its stake in Allena Pharmaceuticals by 70.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,961,144 shares of the company’s stock valued at $2,549,000 after buying an additional 809,035 shares during the last quarter. Worth Venture Partners LLC grew its stake in Allena Pharmaceuticals by 92.1% in the 1st quarter. Worth Venture Partners LLC now owns 980,200 shares of the company’s stock valued at $1,362,000 after buying an additional 470,000 shares during the last quarter. Morgan Stanley grew its stake in Allena Pharmaceuticals by 63.9% in the 2nd quarter. Morgan Stanley now owns 1,045,481 shares of the company’s stock valued at $1,359,000 after buying an additional 407,599 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Allena Pharmaceuticals by 96.7% in the 1st quarter. Renaissance Technologies LLC now owns 485,930 shares of the company’s stock valued at $675,000 after purchasing an additional 238,919 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Allena Pharmaceuticals by 178.9% in the 1st quarter. Geode Capital Management LLC now owns 256,244 shares of the company’s stock valued at $356,000 after purchasing an additional 164,371 shares during the period. Institutional investors and hedge funds own 26.98% of the company’s stock.

Several brokerages have commented on ALNA. Zacks Investment Research cut shares of Allena Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 9th. B. Riley lowered their price objective on shares of Allena Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, August 18th. Finally, HC Wainwright boosted their price objective on shares of Allena Pharmaceuticals from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday, August 11th.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc engages in the development, discovery and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease.

Read More: Earnings Reports

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.